Northern Trust’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.5M | Buy |
1,272,136
+305,843
| +32% | +$4.28M | ﹤0.01% | 1761 |
|
|
2026
Q1 | $12.4M | Buy |
966,293
+93,714
| +11% | +$1.19M | ﹤0.01% | 1954 |
|
|
2025
Q4 | $7.84M | Sell |
872,579
-33,713
| -4% | -$464K | ﹤0.01% | 2209 |
|
|
2025
Q3 | $15.7M | Sell |
906,292
-2,704
| -0.3% | -$33.3K | ﹤0.01% | 1853 |
|
|
2025
Q2 | $8.53M | Sell |
908,996
-8,765
| -1% | -$72K | ﹤0.01% | 2163 |
|
|
2025
Q1 | $6.53M | Sell |
917,761
-61,376
| -6% | -$620K | ﹤0.01% | 2280 |
|
|
2024
Q4 | $11.4M | Buy |
979,137
+112,847
| +13% | +$1.76M | ﹤0.01% | 2049 |
|
|
2024
Q3 | $17.8M | Buy |
866,290
+30,939
| +4% | +$713K | ﹤0.01% | 1694 |
|
|
2024
Q2 | $18.7M | Sell |
835,351
-35,944
| -4% | -$856K | ﹤0.01% | 1594 |
|
|
2024
Q1 | $24M | Sell |
871,295
-15,093
| -2% | -$419K | ﹤0.01% | 1466 |
|
|
2023
Q4 | $27M | Sell |
886,388
-33,999
| -4% | -$977K | ﹤0.01% | 1404 |
|
|
2023
Q3 | $29.1M | Buy |
920,387
+1,865
| +0.2% | +$72.4K | 0.01% | 1298 |
|
|
2023
Q2 | $37.5M | Buy |
918,522
+157,032
| +21% | +$6.37M | 0.01% | 1161 |
|
|
2023
Q1 | $28.4M | Sell |
761,490
-8,370
| -1% | -$328K | 0.01% | 1322 |
|
|
2022
Q4 | $26.9M | Buy |
769,860
+65,086
| +9% | +$3.09M | 0.01% | 1350 |
|
|
2022
Q3 | $39.4M | Buy |
704,774
+717
| +0.1% | +$44.5K | 0.01% | 995 |
|
|
2022
Q2 | $36.4M | Buy |
704,057
+14,446
| +2% | +$734K | 0.01% | 1101 |
|
|
2022
Q1 | $50.1M | Sell |
689,611
-48,192
| -7% | -$4.08M | 0.01% | 1039 |
|
|
2021
Q4 | $87.2M | Sell |
737,803
-5,915
| -0.8% | -$741K | 0.01% | 735 |
|
|
2021
Q3 | $99.8M | Buy |
743,718
+36,421
| +5% | +$5.51M | 0.02% | 654 |
|
|
2021
Q2 | $115M | Buy |
707,297
+62,476
| +10% | +$4.86M | 0.02% | 614 |
|
|
2021
Q1 | $51.8M | Buy |
644,821
+2,914
| +0.5% | +$196K | 0.01% | 1096 |
|
|
2020
Q4 | $34.9M | Sell |
641,907
-9,500
| -1% | -$345K | 0.01% | 1373 |
|
|
2020
Q3 | $12.9M | Buy |
651,407
+179,775
| +38% | +$3.75M | ﹤0.01% | 1933 |
|
|
2020
Q2 | $9.91M | Sell |
471,632
-39,259
| -8% | -$667K | ﹤0.01% | 2100 |
|
|
2020
Q1 | $6.25M | Buy |
510,891
+8,481
| +2% | +$114K | ﹤0.01% | 2173 |
|
|
2019
Q4 | $7.37M | Buy |
502,410
+11,116
| +2% | +$155K | ﹤0.01% | 2372 |
|
|
2019
Q3 | $6.56M | Buy |
491,294
+83,346
| +20% | +$1.33M | ﹤0.01% | 2394 |
|
|
2019
Q2 | $6.68M | Buy |
407,948
+13,737
| +3% | +$216K | ﹤0.01% | 2391 |
|
|
2019
Q1 | $6.73M | Buy |
394,211
+4,281
| +1% | +$63.8K | ﹤0.01% | 2371 |
|
|
2018
Q4 | $5.32M | Sell |
389,930
-3,839
| -1% | -$71.4K | ﹤0.01% | 2462 |
|
|
2018
Q3 | $11.3M | Buy |
393,769
+29,598
| +8% | +$861K | ﹤0.01% | 2190 |
|
|
2018
Q2 | $9.96M | Buy |
364,171
+179,553
| +97% | +$4.35M | ﹤0.01% | 2269 |
|
|
2018
Q1 | $3.89M | Buy |
184,618
+1,782
| +1% | +$43.8K | ﹤0.01% | 2733 |
|
|
2017
Q4 | $3.51M | Buy |
182,836
+30,677
| +20% | +$708K | ﹤0.01% | 2826 |
|
|
2017
Q3 | $3.78M | Buy |
152,159
+115,563
| +316% | +$2.18M | ﹤0.01% | 2811 |
|
|
2017
Q2 | $585K | Sell |
36,596
-39,699
| -52% | -$555K | ﹤0.01% | 3555 |
|
|
2017
Q1 | $1.07M | Sell |
76,295
-1,664
| -2% | -$22.3K | ﹤0.01% | 3320 |
|
|
2016
Q4 | $1.02M | Buy |
77,959
+2,563
| +3% | +$38.5K | ﹤0.01% | 3342 |
|
|
2016
Q3 | $1.28M | Sell |
75,396
-287
| -0.4% | -$5.55K | ﹤0.01% | 3270 |
|
|
2016
Q2 | $1.61M | Buy |
+75,683
| New | +$2.01M | ﹤0.01% | 3154 |
|
Other funds holding NTLA
AIM
RCM
RP
Northern Trust's NTLA Position: Q2 2026 in Review
Northern Trust increased its Intellia Therapeutics (NTLA) stake by 32% in Q2 2026, buying an estimated $4.28M and bringing the position to 1,272,136 shares worth $21.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1761.
Northern Trust first reported a position in NTLA in Q2 2016 and has held it in 41 quarters since. The position peaked at $115M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Northern Trust held 1,272,136 shares of Intellia Therapeutics worth $21.5M as of Q2 2026.
- Northern Trust bought 305,843 Intellia Therapeutics shares in Q2 2026, an estimated $4.28M.
- Intellia Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #1761 holding.
- Northern Trust first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 41 quarters since.
- Northern Trust's Intellia Therapeutics position peaked at $115M in Q2 2021.
- 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.